Clinical trial · Interventional
A Prospective Trial on Nerve Sparing Techniques Performed in Radical Prostatectomy
NCT04393831CI-TRIAL-00057059terminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): This study was terminated to facilitate accrual under NCT05155501
Summary
Brief summary (as posted)
The investigators propose a prospective study to assess recovery of urinary and sexual function by nerve sparing techniques after radical prostatectomy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
| Quality of Life | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Retzius sparing | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Retzius sparing
- description
- Using the Retzius technique, the surgeon will remove the prostate in a way that preserves a portion of the nerves and tissue structures that are typically removed during the conventional technique.
- interventionNames
- Procedure: Retzius sparing
- type
- NO_INTERVENTION
- label
- Conventional (non-Retzius) nerve sparing
- description
- A non-Retzius nerve sparing technique will be performed, according to surgeon's preference--nerve sparing during radical prostatectomy is performed with significant variation and there is an absence of universally agreed upon steps or techniques.
Primary outcomes (3)
- measure
- Number of Treatment-Related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 40 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * clinically localized prostate cancer * able to read and speak English or Spanish * no previous history of head injury, dementia or psychiatric illness * no other concurrent cancer * estimated life expectancy of 10 years or more * biopsy proven prostate cancer Exclusion Criteria: * evidence of metastases * Prostate specific antigen (PSA) greater than 30 ng/mL * previous major pelvic surgery * diagnosis of another malignancy within the past 5 years, with the exception of non-melanoma skin cancer
References
Publications (0)
Data not yet available
No reference posted for this study.